https://kstockbriefing.com
![[Disclosure] ALTEOGEN (196170) – Results of Annual General Meeting of Shareholders / 2026-03-31](https://kstockbriefing.com/wp-content/uploads/2026/08/포맷변환알테오젠.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN held its 18th Annual General Meeting of Shareholders, where all agenda items were approved, including the approval of FY2025 financial statements, a cash dividend of KRW 371 per share (total approx. KRW 20.0B), director and Audit Committee member appointments, and the reduction of capital surplus…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has submitted an IND amendment application to South Korea’s MFDS for the Phase 3 clinical trial of CT-P51 (Keytruda biosimilar) to adjust the number of trial subjects following a revision in its regulatory approval strategy. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment…
![[Disclosure] Samsung Biologics (207940) – (Correction) Submission of Audit Report / 2026-03-26](https://kstockbriefing.com/wp-content/uploads/2026/07/포맷변환-삼성바이오로직스.jpg)
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Samsung Biologics has re-issued its Audit Report to correct the fiscal year end dates for its separate financial statements, reporting FY2025 consolidated revenue of KRW 4.56T and operating profit of KRW 2.07T with an ‘Unqualified’ audit opinion from KPMG Samjong Accounting Corp. 📊 [Key Disclosure Details…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary ALTEOGEN signed an exclusive license agreement with Biogen International GMBH (a subsidiary of Biogen Inc.) to develop and commercialize subcutaneous (SC) formulations of two Biogen biopharmaceutical products using human hyaluronidase (ALT-B4). The total deal value is up to USD 579M (approx. KRW 867.5B, excluding sales royalties)….
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has entered into a global exclusive license-in agreement with KOBIOLABS, Inc. (worth up to KRW 205.2B) for three microbiome candidate strains targeting irritable bowel syndrome with diarrhea (IBS-d) and functional health foods. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint)…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary At Celltrion’s 35th Annual General Meeting of Shareholders, all agenda items were approved, including financial statements (consolidated revenue of KRW 4.16T), a cash dividend of KRW 750 per common share (totaling KRW 164.0B), director appointments, adoption of cumulative voting, and approval of treasury share cancellation plans….
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to retire 9,110,000 common shares of treasury stock (worth approx. KRW 1.72T) held by the company on April 1, 2026, to stabilize share prices and enhance shareholder value. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification…
Read More “[Disclosure] Celltrion (068270) – Decision on Retirement of Shares / 2026-03-24” »
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has announced its Corporate Value-up Program, targeting an average annual revenue growth of over 30% (’25–’27), an ROE of over 7% by 2027, and a 3-year average shareholder return ratio of 40%. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint)…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has restructured its leadership from a three-member to a two-member co-CEO system (Woo-Sung Kee and Jin-Seok Seo) following the re-appointment of CEO Woo-Sung Kee and the resignation of Director Hyoung-Ki Kim. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌…
Fact Source: Financial Supervisory Service DART 💡 3-Second Summary Celltrion has decided to invest KRW 1.23T (6.98% of equity) in new facility construction to build Plants 4 and 5 (total 180,000L capacity) at its Songdo Campus. 📊 [Key Disclosure Details & Financial Summary] 📝 Editor’s Comment (Key Follow-up Checkpoint) 📌 Verification of Songdo Plants 4…
Read More “[Disclosure] Celltrion (068270) – New Facility Investment / 2026-03-24” »